Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational study

Farrukh Shah | Paul Telfer | Mark Velangi | Shivan Pancham | Robert Wynn | Sally Pollard | Elizabeth Chalmers | Jonathan Kell | Angela M. Carter | Joe Hickey | Clark Paramore | Minesh Jobanputra | Kate Ryan

1 Whittington Hospital, London, UK
2 Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK
3 Birmingham Children’s Hospital, Birmingham, UK
4 Birmingham City Hospital, Birmingham, UK
5 Royal Manchester Children’s Hospital, Manchester, UK
6 Bradford Royal Infirmary, Bradford, UK
7 Royal Hospital for Children, Glasgow, UK
8 University Hospital of Wales, Cardiff, UK
9 OPEN Health, Marlow, UK
10 bluebird bio, Cambridge, Massachusetts, USA
11 bluebird bio UK, Basingstoke, UK
12 Manchester Royal Infirmary, Manchester, UK

Correspondence
Farrukh Shah, Department of Haematology, Whittington Hospital, Magdala Avenue, Archway, London, N19 5NF, UK.
Email: farrukh.shah@nhs.net

Funding information
bluebird bio

Abstract

Objectives: We evaluated routine healthcare management, clinical status and patient- and carer-reported outcomes in UK paediatric and adult patients with transfusion-dependent β-thalassaemia (TDT).

Methods: A multi-centre, observational mixed-methodology study evaluated 165 patients (50% male; median age 24.1 [interquartile range (IQR)] 11.8–37.2] years) from nine UK centres.

Results: Patients had a mean of 13.7 (standard deviation [SD] ± 3.2) transfusion episodes/year (mean retrospective observation period 4.7 [±0.7] years). The median (IQR) for iron overload parameters at the last assessment during the observation period were: serum ferritin (n = 165) 1961.0 (1090.0–3003.0) μg/L (38% > 2500 μg/L); R2 liver iron (n = 119) 5.4 (2.9–11.6) mg/g (16% ≥ 15 mg/g); T2* cardiac iron (n = 132) 30.3 (22.0–37.1) ms (10% < 10 ms). All patients received ≥1 iron chelator during the observation period; 21% received combination therapy. Patients had a mean of 7.8 (±8.1) non-transfusion-related hospital attendances or admissions/year. Adult patients’ mean EQ-5D utility score was 0.69 (±0.33; n = 94 [≥16 years]) and mean Transfusion-dependent quality of life score was 58.6 (±18.4; n = 94 [≥18 years]). For Work Productivity and Activity impairment, mean activity impairment for patients ≥18 years (n = 88) was 48% (±32%) and for carers (n = 29) was 28% (±23%).

Conclusions: TDT presents significant burden on patients, carers and healthcare resources.

KEYWORDS
blood transfusion, healthcare resource use, iron chelation therapy, quality of life, transfusion-dependent β-thalassaemia
Transfusion-dependent β-thalassaemia (TDT; an inherited blood disorder requiring lifelong, regular blood transfusions and iron chelation therapy (ICT) [1–3]. Blood transfusions lead to iron overload requiring regular monitoring and optimisation of ICT to mitigate complications; however, this intensive therapy and monitoring imposes a great burden on patients and their families [4–8]. Complications associated with iron overload include endocrine dysfunction and hepatic pathology; cardiac disease is the most serious, leading to arrhythmias and heart failure, and early mortality [1,3,9]. While life expectancy for patients with TDT has significantly improved in the past 50 years in the United Kingdom (UK) [10], the crude 10-year mortality rate for patients with TDT in England was recently reported as more than five times higher than the age/sex adjusted general population (6.2% vs. 1.2%; p < 0.001) [11], suggesting that despite care delivered in a high-income setting, mortality from TDT remains significantly higher than the general population.

Until recently, allogeneic haematopoietic stem cell transplantation (allo-HSCT) was the only potentially curative treatment. Allo-HSCT is generally reserved for paediatric patients with a human leukocyte antigen-matched related donor (25–30% of patients [12]), and not routinely offered for UK adult patients [3]. Recent advances in gene therapy have increased the avenues for potentially transformative treatments for TDT [13]. An understanding of the routine management of TDT and associated burden on patients, carers and healthcare resources is important in evaluating the impact of emerging treatments.

The present study evaluated current management pathways for TDT, clinical status, healthcare resource use, and the impact of TDT on quality of life (QoL) and work productivity of patients and carers in the United Kingdom.

2 | METHODS

2.1 | Study design and setting

A multi-centre, observational mixed-methodology study, involving a retrospective chart review and cross-sectional survey of paediatric and adult patients with TDT and their carers, was conducted in nine UK National Health Service (NHS) centres. The study observation period for eligible patients with TDT diagnosed ≥5 years prior to data collection was the 5-year period prior to data collection or death; for patients with TDT diagnosed 2–5 years prior to data collection it was the period from TDT diagnosis to data collection or death (Figure 1). Baseline was defined as the start of the patient’s observation period. Centres were selected in order to give a good geographical spread (including centres in England, Scotland and Wales) and to be representative of practice across the range of centres managing patients with TDT in the UK, including adult haematology centres, paediatric only centres and centres managing both adult and paediatric patients. Potential centres were identified and selected based on a feasibility questionnaire and meeting; with the number of potentially eligible patients in the selected centres ranging between 5 and 53.

2.2 | Participants

2.2.1 | Patients with TDT

Patients with TDT or with TDT recurrence after allo-HSCT ≥2 years prior to data collection were eligible for inclusion. TDT, or TDT recurrence post-allo-HSCT, was defined as follows: β-thalassaemia treated with a minimum of eight transfusion episodes during the first year of chronic transfusion therapy (or the first year of chronic transfusion therapy after recurrence post-allo-HSCT) or transfusion of at least 100 mL/kg/year of red blood cells.

For the retrospective chart review, exclusion criteria included patients who remained TDT-free post-allo-HSCT, patients with <2
2.2.2 | Carers of patients with TDT

The carers (parents or carers) of patients completing the patient survey were eligible for the carer survey if they were aged ≥16 years and had no significant mental or English language incapacity preventing them from participating.

2.2.3 | Patient and carer consent

Living patients (or their carer, as appropriate for age), and carers participating in the survey provided written informed consent according to the protocol approved by the NHS Heath Research Authority (London–Harrow Research Ethics Committee reference: 17/LO/2114; 14 March 2018). For deceased patients, data were collected by members of the direct care team to preserve patient confidentiality.

2.3 | Endpoints and data collection

The primary endpoint was the number of blood transfusion episodes/patient/year. Secondary endpoints included: metrics of routine management of TDT (including transfusions and ICT); patients' clinical status, TDT treatment-related complications and comorbidities (as documented in medical records); TDT-related healthcare resource utilisation (including hospital attendances, admissions and iron overload assessments); and patient and carer QoL. For the retrospective chart review, anonymised data were collected from written and electronic hospital record systems using standard electronic data collection forms designed specifically for the study. All staff involved in data collection were trained in the requirements for the study documentation. Data were checked for completeness and accuracy using manual and programmed validation checks and queries resolved through discussion with centre investigators. Data collection was undertaken between June 2018 and July 2019.

Patients and carers completed three validated questionnaires (using anonymised paper-based questionnaires) evaluating different aspects of QoL and work productivity, using age-appropriate and carer-specific versions where available (see Supporting Information Supplementary Table S1). General health status was evaluated using the generic EuroQol EQ-5D 3 level (EQ-5D-3L) questionnaire [14–16]. TDT-specific QoL was evaluated using the Transfusion-dependent QoL (TranQoL) questionnaire [17,18]. TDT impact on work and daily activities was evaluated using the Work Productivity Activity Index (WPAI) questionnaire [19–21].

The EQ-5D-3L questionnaire was used (under licence) to assess the general health status of patients and their carers on the day of completion. Adults (≥16 years) were administered the EQ-5D-3L and children (8–15 years) were administered the EQ-5D-Y, a child-friendly EQ-5D version. A proxy version of the EQ-5D-Y was administered only to carers of children between the ages of 4–7 years, which required the proxy to rate the health of the child. No version of the EQ-5D-Y is available for children aged under 4 years [14–16]. The EQ-5D-3L comprised two parts. The first evaluated five dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on three levels (level 1: no problems; level 2: some problems; level 3: extreme problems) to give a 5-digit health state that was converted to a summary health utility score ranging from 1 (perfect health) to < 0 (0 is equivalent to death and negative values represent states worse than death) using the UK value set [22]. There is currently no value set for the self-completed EQ-5D-Y (8–15 years); therefore, utility scores could not be calculated for this age group [14]. The second part of the EQ-5D-3L used a visual analogue scale (VAS) to assess self-rated health from 0 (worst imaginable) to 100 (best imaginable). The EQ-5D-Y measured the same dimensions as the EQ-5D-3L worded in a manner suitable for completion by children.

TDT-related QoL for patients and carers was assessed using the TranQoL questionnaire (under a user agreement). Adults (≥18 years) were administered the adult version, carers were administered the parent version to complete about themselves, children (7–17 years) were administered the child version. A proxy version of TranQoL was administered only to carers of children <7 years of age [17,18]. TranQoL is a thalassaemia-specific QoL instrument that assesses the impact of disease over the 7 days prior to completion on physical health, emotional functioning, family functioning and school and career.
functioning, with the adult version also covering sexual activity. The individual domain scores and the TranQoL overall score range from 0 to 100, with higher scores representing better QoL[18].

The impact of TDT was also assessed using the WPAI questionnaire for adult patients (≥ 18 years) and carers only; the WPAI specific health problems (SHP) version for patients and the caregiver (WPAI:CG) version for carers were used as appropriate [19–21]. The WPAI assesses the impact of disease on work productivity over the 7 days prior to completion by evaluating absenteeism (the amount of work time missed), presenteeism (impaired working effectiveness [WPAI definition]) and overall work productivity loss (absenteeism and presenteeism), as well as assessing activity impairment (impact on non-work related activities). Domain scores are expressed as percent impairment, with higher scores indicating a greater degree of impairment [19,20].

2.4 Statistical analyses

Normally distributed quantitative variables and variables describing hospital resource utilisation are presented as mean (± standard deviation). Non-normally distributed quantitative variables are presented as medians (interquartile range [IQR]). Distributions are presented where appropriate. Categorical variables are described as frequency (percentage). Annualised variables were estimated after excluding periods with missing data. Results for haemoglobin tests were batch-exported; haemoglobin assessments were classified as pre-transfusion haemoglobin assessments if they occurred within 3 days prior to a transfusion episode.

Post hoc analyses were conducted to evaluate the relationships between selected endpoints and cut-off points for iron burden based on UK Thalassaemia Society Standards for serum ferritin (low serum ferritin: <500 μg/L; recommended serum ferritin: 500–1000 μg/L; moderate serum ferritin: >1000 to ≤ 2500 μg/L; high serum ferritin: >2500 μg/L), liver iron R2 concentration (low liver iron: <3 mg/g; recommended liver iron: 3–7 mg/g; moderate liver iron: >7 to <15 mg/g; high liver iron: ≥ 15 mg/g) and cardiac iron T2* concentration (normal cardiac iron: >20 ms; moderate cardiac iron: 10–20 ms; severe cardiac iron: <10 ms; very severe cardiac iron: <6 ms) [3].

Percentages are rounded to the nearest whole number (hence may not sum to 100%). All analyses were conducted using only available results and denominators presented where data were missing.

3 RESULTS

3.1 Patient demographics and clinical characteristics

Patient demographics and clinical characteristics are summarised in Table 1. The study included 165 patients with TDT (median age 24.1

| TABLE 1 | Patient demographics and clinical characteristics |
|----------|--------------------------------------------------|
| Demographic and clinical characteristics | Patients with TDT (n = 165) |
| Age at the end of the observation period (years), median (IQR) | 24.1 (11.8–37.2) |
| Age distribution, n (%) | |
| <12 | 42 (25%) |
| 12 < 18 | 19 (12%) |
| 18 < 30 | 42 (25%) |
| 30 < 40 | 29 (18%) |
| 40 < 50 | 18 (11%) |
| 50 < 60 | 12 (7%) |
| ≥60 | 3 (2%) |
| Male, n (%) | 82 (50%) |
| Ethnicity, n (%) | n = 148 |
| Pakistani | 49 (33%) |
| Bangladeshi | 18 (12%) |
| Indian | 17 (11%) |
| Chinese | 7 (5%) |
| White and Asian | 1 (1%) |
| Any other Asian background | 19 (13%) |
| White and Black African | 1 (1%) |
| Any other White background | 28 (19%) |
| Any other Black background | 1 (1%) |
| Any other Mixed background | 3 (2%) |
| Other ethnic group | 4 (3%) |
| Not stated | 17 |
| Comorbidities at baseline | n = 156 |
| None | 49 (31%) |
| ≥1 | 107 (69%) |
| Not known | 9 |
| Comorbidities recorded in ≥5 patients, n (% of 156) | |
| Hypogonadotropic hypogonadisma | 31 (20%) |
| Splenectomya | 31 (20%) |
| Cardiac diseasea | 26 (17%) |
| Vitamin D Deficiency | 25 (16%) |
| Osteoporisa | 22 (14%) |
| Diabetesa | 20 (13%) |
| Hepatitisa | 16 (10%) |
| Osteopeniaa | 13 (8%) |
| Hypothyroidisma | 12 (8%) |
| Asthma | 11 (7%) |
| Hypogonadism | 11 (7%) |
| Growth failurea | 9 (6%) |
| Eczema | 8 (5%) |
| Liver iron overloada | 7 (4%) |

(Continues)
TABLE 1 (Continued)

| Demographic and clinical characteristics | Patients with TDT (n = 165) |
|-----------------------------------------|-----------------------------|
| Impaired glucose tolerance\textsuperscript{a} | 7 (4%)                      |
| Hypoparathyroidism\textsuperscript{a}   | 6 (4%)                      |
| Other                                   | 81                          |
| Duration of TDT at baseline (years), median (IQR) | 9.5 (3.6–18.5), n = 112 |
| Age at TDT diagnosis (years), median (IQR) | 1.0 (0.5–8.0), n = 107 |

\textsuperscript{a}Comorbidities likely to be TDT-related. IQR: interquartile range. TDT: transfusion-dependent \( \beta \)-thalassaemia.

[IQR 11.8–37.2] years, 25% aged <12 years; 50% male; 70% were of Asian origin, that is Pakistani, Bangladeshi, Indian or mixed Asian origin; two patients had recurrence of TDT after allo-HSCT; one patient was deceased. Of 156 patients with baseline comorbidity data, 69% had \( \geq 1 \) comorbidity (most commonly hypogonadotropic hypogonadism [20%], splenectomy [20%], cardiac disease [17%] and vitamin D deficiency [16%]).

### 3.2 Transfusion episodes, cross-matching and haemoglobin assessments

During a mean observation period of 4.7 (±0.7) years, patients had a mean of 13.7 (±3.2) transfusion episodes/year (see Supporting Information Table S2 and Figure S1) and 13.7 (±3.2) attendances for cross-matching/patient/year (99% [10509/10592] of all cross-matching tests were recorded on a different date to the transfusion). The mean volume of blood transfused was 175.5 (±57.5) mL/kg/year (\( n = 84 \) patients with volume and weight recorded). Patients had a mean of 10.7 (±4.8) pre-transfusion haemoglobin tests/year; the mean pre-transfusion haemoglobin was 99.5 (±10.1) g/L during the observation period (\( n = 8473 \) tests).

### 3.3 Iron burden and iron chelation therapy

Patients had a mean of 11.4 (±4.1) serum ferritin tests/year; the median serum ferritin concentration during the observation period was 1.544.0 (IQR 936.0–2640.0) \( \mu \)g/L (\( n = 8433 \) tests). The median serum ferritin at patients’ last documented assessment during the observation period was 1961.0 (IQR 1090.0–3003.0) \( \mu \)g/L: 5% had low serum ferritin (<500 \( \mu \)g/L), 17% had recommended serum ferritin (500–1000 \( \mu \)g/L), 39% had moderate serum ferritin (>1000 to ≤2500 \( \mu \)g/L) and 38% had high serum ferritin (>2500 \( \mu \)g/L; Figure 2A).

Data on liver iron concentration (LIC) and cardiac iron assessments were available for \( n = 145 \) and \( n = 137 \) patients, respectively (assessed by any method). In the overall patient population, patients had a mean of 0.5 (±0.3) LIC/year (most commonly assessed by R2 magnetic resonance imaging [MRI]) and 0.4 (±0.3) cardiac iron assessments/year (most commonly T2* MRI). The median LIC at the last R2 assessment was 5.4 (IQR 2.9–11.6) mg/g (\( n = 119 \)); 26% (31/119) had low LIC (<3 mg/g), 34% (41/119) had recommended LIC (3–7 mg/g), 24% (28/119) had moderate LIC (>7 to <15 mg/g) and 16% (19/119) had high LIC (≥15 mg/g; Figure 2B). The median cardiac T2* at the last assessment was 30.3 (IQR 22.0–37.1) milliseconds (ms) (\( n = 132 \)); 80% (105/132) had normal cardiac iron (>20 ms), 11% (14/132) had moderate cardiac iron (10–20 ms) and 10% (13/132) had severe cardiac iron (<10 ms, Figure 2C; 4/132 patients [3%] had very severe cardiac iron loading [<6 ms]).

![Figure 2](image-url)
In post hoc analyses, 44% of patients had average intervals of <2 years between LIC assessments and 29% had intervals of <2 years between cardiac iron assessments (Supplementary Figure S2). Intervals of <2 years were observed for 43% of patients with high LIC and 54% of patients with severe cardiac iron at the last assessment during the observation period (Supplementary Figure S3). The proportion of patients with an interval of <2 years between assessments of LIC and cardiac iron stratified by age at baseline are summarised in Supplementary Figure S4.

The median age at initiation of ICT was 2.9 (IQR 1.8–12.1) years (n = 91 patients with date of ICT initiation available). All patients received ≥1 iron chelator during the observation period, and 162 patients were receiving ICT at the end of the observation period (deferiprone: 58%; deferasirox: 14%; deferoxamine: 7%; combination therapy: 21% [11% deferoxamine/deferiprone, 5% deferasirox/deferiprone, 5% deferasirox/deferoxamine]). Non-adherence to ICT at any point during the observation period was documented in medical records for 25% of patients (23% of patients taking deferasirox, 12% of patients taking deferoxamine, 8% of patients taking deferoxamine and 3% of patients taking combination therapy). Non-adherence was most commonly related to difficulties with compliance or incorrect dosing/frequency of dosing.

Overall, 28% of patients had at least one ICT-related adverse event (AE) documented (Supplementary Table S3). Of the 132 patients prescribed deferasirox at any time during the observation period, 37 (28%) experienced a total of 64 deferasirox-associated AEs, most commonly (each accounting for ≥5 deferasirox-associated AE events) abdominal pain (30% of events) and hepatic impairment (14% of events); 50% of deferasirox-associated AEs resulted in a change in ICT and 28% required treatment (Supplementary Tables S3 and S4). Of the 57 patients prescribed deferiprone, four (7%) experienced a total of nine different deferiprone-associated AEs; 56% of these resulted in a change in ICT and 56% required treatment (Supplementary Tables S3 and S4). Of the 85 patients prescribed deferoxamine, 11 (13%) experienced a total of 25 deferoxamine-associated AEs (each accounting for less than five deferoxamine-associated AE events); 16% of these resulted in a change in ICT and 48% required treatment (Supplementary Tables S3 and S4).

3.4 | TDT-related hospital attendances and admissions

In addition to attendances for blood transfusions and cross-matching described above, ≥1 transfusion-related outpatient attendance, day case admission, emergency department (ED) attendance, and inpatient admission were recorded for n = 159, n = 51, n = 57 and n = 41 patients, respectively (Supplementary Table S2). In the overall population, patients had a mean of 7.0 (±7.8) non-transfusion-related outpatient attendances/year (83% haematology [4545/5461 attendances]), a mean of 0.5 (±1.6) non-transfusion-related day case admissions/year, a mean of 0.2 (±0.4) ED attendances/year (30% resulting in admission) and a mean of 0.1 (±0.3) inpatient admissions/year (Supplementary Table S2). The mean length of stay for inpatient admissions was 5.6 (±6.2) days. Overall, patients had a mean of 7.8 (±8.1) non-transfusion-related hospital attendances or admissions/year. Fewer than 5% of non-transfusion-related outpatient attendances, day case admissions and inpatient admissions were to cardiology or endocrinology (Supplementary Table S2).

3.5 | TDT treatment-related complications and comorbidities newly recorded during the observation period

A mean of 0.4 (±0.3) iron overload complications were diagnosed/patient/year, most commonly (≥5 patients during the observation period) cardiac complications (11 [7%] patients, including one death due to cardiogenic shock), growth retardation (nine [5%] patients), hypothyroidism (seven [4%] patients), hepatic complications (seven [4%] patients) and diabetes (five [3%] patients). The comorbidities newly diagnosed during the observation period in ≥5 patients were vitamin D deficiency (16 [10%] patients) and recurrent urinary tract infections (six [4%] patients). No newly diagnosed infectious complications from blood transfusion were recorded.

3.6 | Patient- and carer-reported outcomes

At least one patient-reported outcome questionnaire was completed for 134/165 (81%) patients, with a median (IQR) time from diagnosis to questionnaire completion of 14.4 (8.0–23.4) years (n = 85 completed questionnaires and had date of diagnosis recorded). At least one carer-reported outcome questionnaire was completed by 37 carers. In terms of general health status, an EQ-5D-3L utility score of 1 equates to perfect health and 0 equates to death. For the study population, the mean EQ-5D-3L utility score in patients aged ≥16 (n = 94) was 0.69 (±0.33), in patients aged 4–7 (proxy; n = 9) was 0.73 (±0.27) and in carers (n = 34) was 0.88 (±0.15); for reference, the age-weighted utility score for a UK general adult population is 0.91; see Figure 3A (there is currently no value set for the self-completed EQ-5D-Y [8–15 years], therefore no utility scores could be calculated for this age group). The problems reported by participants across the EQ-5D-3L individual QoL domains of anxiety/depression, pain, usual activities, self-care and mobility are summarised in Figure 3B–E; moderate or extreme problems with pain were reported by ≥50% of patients in each age group (Figure 3B–D). The mean EQ-5D-3L VAS scores are summarised in Supplementary Table S5.

For the TranQoL thalassaemia-specific QoL instrument, a total TranQoL score of 100 represents the best and a score of 0 the worst disease-related QoL for an individual living with TDT. The mean TranQoL score in patients aged ≥18 (n = 94) was 58.6 (±18.4), which represents notable impairment in QoL as related to living with TDT. Disease-related QoL was also impacted in patients aged 7–17 (n = 27; mean score of 74.8 [±15.0]), in patients aged <7 (n = 13; proxy mean score
FIGURE 3  Patient and carer general health state assessed using age-appropriate EQ-5D-3L questionnaires. Panel A: EQ-5D-3L utility score (1 equates to perfect health, 0 equates to death and negative values represent states worse than death [14]) calculated using the UK value set [22]; there is currently no value set for the self-completed EQ-5D-Y (8–15 years), therefore utility scores could not be calculated for this age group; the UK reference value was calculated from published age-specific UK population norms weighted for the age-distribution of the adult patients assuming the population norm for age 16–17 years was equivalent to age 18–24 years [43]; X indicates the mean. Panels B–E: Proportion of patients reporting problems according to EQ-5D-3L dimension level (B: adult patients ≥16 years; C: children 8–15 years; D: children 4–7 years [proxy]; E: carers). EQ-5D-3L domains were classified as level 1: no problems; level 2: moderate problems; level 3: extreme problems. (note: boxes represent the 25th percentile, 50th percentile [median] and 75th percentile of ranked scores; for the Carer utility score, the 50th and 75th percentile were 1.0 and consequently both are indicated by the top line of the box)
FIGURE 4 Patient and carer TDT-related quality of life assessed using the TranQoL questionnaire. Panel A: Patient and carer TranQoL overall scores; X indicates the mean. Panel B: Patient TranQoL domain scores. TranQoL score and individual domain scores range from 0 (worst thalassaemia-related QoL) to 100 (best thalassaemia-related QoL). X indicates the mean. (Note: boxes represent the 25th percentile, 50th percentile [median] and 75th percentile of ranked scores; for the Sexual Health domain scores the 25th and 50th percentiles were 50, and consequently both are indicated by the bottom line of the box)

4 | DISCUSSION

This study provides a contemporary (2018–2019) and comprehensive picture of the substantial impact of TDT on the daily lives of patients and their carers, and the significant burden on secondary healthcare resources in the UK. Patient demographics were consistent with the wider population of patients with thalassaemia [11,23]. Based on recent data from England [24], we estimate that the study included approximately 15% of the UK population of patients with TDT. Comorbidities and TDT-related complications were commonplace, with the latter representative of the spectrum of well-documented complications [3,11,25,26].

Patients had a mean of 13.7 blood transfusion episodes/year, consistent with a recent UK Hospital Episodes Statistics database study [11]. In addition, patients had an average of 13.7 cross-match attendances and 7.8 other TDT-related hospital attendances and admissions annually, equating to almost three TDT-related appointments/month in total. The frequent hospital attendances and admissions have potential financial implications for patients and their families in terms of out-of-pocket expenses and impact on employment, as well as representing a considerable burden on healthcare resources [8,27–30].

Despite management in specialist centres, significant iron overload affected a subset of patients; 10% had severe cardiac iron loading, 16% high LIC and 38% high serum ferritin at the last assessment and one patient died due to cardiogenic shock. Chronic iron overload is associated with significant morbidity and mortality and, despite advances in ICT and monitoring, iron-related cardiomyopathy remains the most frequent cause of death in patients with TDT [3,9,31–33]. Cardiac T2*...
iron was reported as the strongest predictor of cardiac iron-related comorbidities, with 47% of patients with a cardiac T2* of < 6 ms developing heart failure within 12 months [32], emphasising the importance of regular iron overload monitoring. The UK Thalassaemia Society Standards recommend assessing cardiac iron every 6 months for patients with severe cardiac iron (<10 ms) and assessing LIC every 12 months for patients with moderate/high LIC (>7 mg/g) [3]. In post hoc analyses, we observed only 43% of patients with high LIC and 54% of patients with severe cardiac iron at the last recorded assessment had intervals of <2 years between assessments during the observation period. The study did not formally assess the underlying rationale for frequency of iron monitoring; however, inclusion of paediatric patients below the recommended age (7–10 years) for commencing MRI assessment of cardiac iron [3] may have contributed in part to the observation.

Although all patients received ICT at some point during the observation period, the proportion of patients with high iron burden suggests that iron overload was inadequately controlled by ICT in some patients. Consistent with this, 21% of patients were receiving combination ICT at the end of the observation period, most commonly deferiprone and desferrioxamine, which is recommended to improve cardiac iron deposition [3,34,35]. High iron burden may also partly reflect non-adherence to ICT and at least one non-adherence event was documented in 25% of patients; however, non-adherence to desferrioxamine was lower than expected based on previously published patient-reported and carer-reported adherence [36]. The reason for this is unclear, but may partly reflect under-reporting in routine clinical practice. Equally, patients on desferrioxamine may represent a motivated population who were managing complications and/or had good adherence with effective iron control and did not wish to switch to oral therapy. Non-adherence to ICT has been suggested to limit the survival advantage afforded by full adherence [37] and may be influenced by age, difficulties with administration, the life-long nature of treatment and the occurrence of side effects [36,38]. In this context, AEs associated with ICT were common, and approximately 50% of all AEs required treatment, adding to the burden of routine management of TDT on patients and healthcare resources.

The adverse impact of TDT on QoL, reflecting the burden of frequent transfusions, monitoring and management of iron overload, treatment-related AEs, TDT-related comorbidities and other TDT-related hospital attendances/admissions, has been described in various countries and using a variety of instruments [4–8,39–42].

**FIGURE 5** Patient and carer TDT-related quality of life assessed using the WPAI questionnaire. Panel A: Adult patient domain scores for WPAI for specific health problems (WPAI-SHP). Panel B: carer WPAI (WPAI-CG) domain scores. The WPAI assesses the impact of disease on work productivity by evaluating absenteeism (the amount of work time missed), presenteeism (impaired work effectiveness [WPAI definition]) and overall work productivity loss (absenteeism + presenteeism); non-work related activity impairment is also assessed [19,20]. Domain scores are expressed as the percent impairment for work/activities. Scores range between 0% (no impairment) to 100% (complete impairment). X indicates the mean. (note: boxes represent the 25th percentile, 50th percentile [median] and 75th percentile of ranked scores)
study provides further evidence of the substantial impact of TDT on a range of domains of daily living assessed using generic and disease-specific instruments. The mean EQ-5D-3L utility score of 0.69 for adult patients suggests poorer QoL in comparison with the UK general population based on an age-weighted mean of 0.91 estimated from published age-specific UK population norms [43]. TranQoL is a recently developed TDT-specific QoL questionnaire [17,18], and, apart from the original studies, only studies using translated versions of TranQoL have been published with variable results [39,40,44], most likely reflecting differing social and healthcare environments. The mean TranQoL scores of adult patients and carers were broadly similar, suggesting a comparable impact of TDT on their QoL. Further studies of TranQoL are warranted to understand the factors influencing TDT-related QoL in patients across the age spectrum. To the best of our knowledge, we show for the first time using the WPAI the marked impact of TDT on work productivity and general activity for both patients and carers. The impact on carers was similar to that reported for carers of chronically ill older people [21]. The impact on work productivity most likely reflects the frequency of routine TDT-related daytime hospital attendances, particularly for cross-matching and transfusions. Healthcare providers should examine how services can be adapted to ensure that transfusion-related attendances are managed efficiently to minimise impacts on work and education. Taken together, the results of the present study emphasise the significant impact of TDT on the QoL of patients and their carers, with the extent to which children are affected by TDT across a range of domains of daily living particularly notable. Further studies are warranted to evaluate the impact of TDT on the daily lives of patients and their families over time.

Limitations of the study include the retrospective design and reliance on the quality of recording in source medical records. Furthermore, the generalisability to the wider population may be limited by the study’s requirement for consent from living patients, and not all participants completing all questions.

5 CONCLUSIONS

These results offer important insights into the real-world management and clinical status of patients with TDT in the UK, and underscore the significant burden of the condition on patients, carers and healthcare resources. In general, patients from the centres included appear to have been well managed; however, an important subset of patients suffer severe liver and cardiac iron loading, the latter being associated with significant mortality risk. The impact of the disease on the QoL of patients, in particular children, and their carers, should not be underestimated as evidenced by the range of domains of daily living that are affected.

ACKNOWLEDGEMENTS
This study was funded by bluebird bio, who were involved in study design, interpretation of the data, and the drafting, revision and final approval of this manuscript for submission.

The authors would like to thank all the patients and their carers for participating in this study. The authors thank pH Associates Ltd, doing business as OPEN Health, a healthcare consultancy company specialising in real-world evidence, who were commissioned by bluebird bio to provide support for study design and implementation, data analysis and interpretation, and medical writing support (M Watt) in the drafting and submission of this manuscript.

CONFLICT OF INTEREST
FS declares advisory board (silence therapeutics, Roche, Novartis, bluebird bio, Celgene), clinical safety committee (Abbero pharmaceuticals) and steering committee for trial (Celgene) involvement; PT declares advisory committee (Global Blood Therapeutics, Novartis, bluebird bio), data monitoring committee (Pfizer), clinical trial activity (Apopharma, Celgene, Global Blood Therapeutics, Novartis, Napp Pharma), investigator led funding (Kyowa Kirin Limited, bluebird bio) and speaker activity (Apopharma, Terumo plc); MV states advisory board activity for bluebird bio; SPancham declares advisory board (Celgene and Novartis) and sponsorship to attend educational meeting (Celgene); RW states nothing to declare; SPollard declares Novartis support to attend educational meetings, advisory board activity for bluebird bio; EC declares consultancy fees from Novartis; JK declares advisory boards with Celgene, Jazz and Novartis; AMC and JH are employees of pH Associates Ltd, doing business as OPEN Health; CP and MJ are employees of bluebird bio and own stock in the company; KR declares advisory boards for bluebird bio and Pfizer, Educational grant from Novartis. The study was funded by bluebird bio, Inc. bluebird bio, Inc. has a gene therapy for β thalassaemia currently licensed in the EU.

AUTHOR CONTRIBUTIONS
FS, PT, MV, SPancham, RW, SPollard, EC, JK and KR were involved in the acquisition and interpretation of data, critical revision of the manuscript and approval of the final version for submission. AMC was involved in study design, interpretation of data, drafting and revision of the manuscript and approval of the final version for submission. JH was involved in study design, analysis and interpretation of data, critical revision of the manuscript and approval of the final version for submission. CP and MJ were involved in study design, interpretation of data, critical revision of the manuscript and approval of the final version for submission.

DATA ACCESSIBILITY STATEMENT
How or where can the data be obtained?
Appropriately de-identified patient-level datasets and supporting documents may be shared following attainment of applicable marketing approvals and consistent with criteria established by bluebird bio and/or industry best practices to maintain the privacy of study participants. For more information please contact datasharing@bluebirdbio.com.

When will data availability begin?
Upon request following attainment of applicable marketing approvals.
REFERENCES

1. Galanello R, Orga R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
2. Musallam KM, Angastiniotis M, Eleftheriou A, Porter JB. Cross-talk between available guidelines for the management of patients with beta-thalassaemia major. Acta Haematol. 2013;130:64–73.
3. UK Thalassaemia Society Standards for the clinical care of children and adults with thalassaemia in the UK. 3rd Edition. [Internet]. 2016 (accessed 10 Aug 2021). https://uks.org/3d-flip-book/standards/https://uks.org/3d-flip-book/standards/
4. Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert DA, et al. Quality of life in thalassemia: A comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2011;86:92–5.
5. Liem RI, Gilgour B, Pelligr SA, Mason M, Thompson AA. The impact of thalassemia on Southeast Asian and Asian Indian families in the United States: A qualitative study. Ethn Dis. 2011;21:361–9.
6. Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res. 2014;23:2277–88.
7. Thuret I, Hacini M, Pégourié-Bandelier B, Gardembas-Pain M, Bisot-Locard S, Merlat-Guitard A, et al. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. Hematology. 2009;14:315–22.
8. Clarke SA, Skinner R, Guest J, Darbishire P, Cooper J, Shah F, et al. Health-related quality of life and financial impact of caring for a child with thalassaemia major in the UK. Child Care Health Dev. 2010;36:118–22.
9. Ladis V, Choularias G, Berdoukas V, Chatziliami A, Fragodimitri C, Karabatsos F, et al. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassemia and mortality ratios compared to the general population. Eur J Haematol. 2011;86:322–8.
10. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
11. Jobanputra M, Paramore C, Laird SG, McGahan M, Telfer P, et al. Cormorbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis. Br J Haematol. 2020;191:897-905.
12. Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99:811–20.
13. Srivastava A, Shahi RV. Cure for thalassemia major – from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017;102:214–23.
14. EuroQol. EQ-5D-3L [Internet] 2019 (accessed 10 Aug 2021). https://euroqol.org/eq-5d-instruments/
15. van Reenen M & Oppe M EQ-5D-3L user guide [Internet]. 2018 (accessed 10 Aug 2021). https://euroqol.org/publications/user-guides/
16. van Reenen M, Janssen B, Oppe M, Kreimeier S & Greiner W EQ-5D-Y user guide [Internet]. 2020 (accessed 10 Aug 2021). Available from: https://euroqol.org/publications/user-guides/
17. Klaassen R, Allibhai S, Kirby Allen M, Moreau K, Merelles-Pulcini M, Forgione M, et al. Introducing the TranQol: a new disease-specific quality of life measure for children and adults with thalassemia major. J Blood Disord Transfus. 2013;4:1–5.
18. Klaassen RJ, Barrowman N, Merelles-Pulcini M, Vichinsky EP, Sweeters N, Kirby-Allen M, et al. Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia major. Br J Haematol. 2014;164:431–7.
19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment questionnaire. Pharmacoeconomics. 1993;4:353–65.
20. Reilly Associates Work Productivity and Activity Impairment Questionnaire [Internet]. 2019. (accessed 10 Aug 2021). http://www.reillyassociates.net/WPAI_General.html
21. Giovannetti ER, Wolff JL, Frick KD, Boult C. Construct validity of the work productivity and activity impairment questionnaire across informal caregivers of chronically ill older patients. Value Health. 2009;12:1011–7.
22. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108.
23. National Haemoglobinopathy Registry National Haemoglobinopathy Registry annual report for 2018/2019 [Internet]. 2018 (accessed 09 Dec 2020). https://nhr.mdsas.com/
24. National Haemoglobinopathy Registry NHR: number of patients by diagnosis [Internet]. 2020 (accessed 10 Aug 2021). http://nhr.mdsas.com/wp-content/uploads/2020/06/NumberPatientsDiagnosis.pdf
25. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104:34–9.
26. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.
27. Scalone L, Mantovani LG, Krol M, Rouill D, Ravera S, Bisconte MG, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24:1905–17.
28. Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion (Paris). 2016;56:1038–45.
29. Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. Life-time treatment costs of beta-thalassaemia major. Clin Lab Haematol. 1999;21:377–85.
30. Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 2019;37:100588.
31. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128:281–308.
32. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961.
33. Farmakis D, Giakoumis A, Angastiniotis M, Eleftheriou A. The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation. Eur J Haematol. 2020;105:16–23.
34. Ceci A, Mangiariini L, Felisi M, Bartoloni F, Ciancio A, Capra M, et al. The management of iron chelation therapy: Preliminary data from a national registry of Thalassaemic patients. Anemia. 2011;2011:435683.
35. NHS England Treatment-of-iron-overload-for-transfused-and-non-transfused-patients-with-chronic-inherited-anaemias [Clinical Commissioning Policy 16070/P] [Internet]. 2016. (accessed 10 Aug 2021). https://www.england.nhs.uk/wp-content/uploads/2018/07/Treatment-of-iron-overload-for-transfused-and-non-transfused-patients-with-chronic-inherited-anaemias.pdf
36. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86:433–6.
37. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet Lond Engl. 2000;355:2051–2.

38. Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Rev. 2018;32:300–11.

39. Yasmeen H, Hasnain S. Quality of life of Pakistani children with β-thalassemia major. Hemoglobin. 2018;42:320–5.

40. Klonizakis P, Klaassen R, Sousos N, Liakos A, Tsapas A, Vlachaki E. Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. Ann Hematol. 2017;96:1937–44.

41. Javanbakht M, Keshtkaran A, Shabaminejad H, Karami H, Zakerinia M, Delavari S. Comparison of blood transfusion plus chelation therapy and bone marrow transplantation in patients with β-thalassemia: application of SF-36, EQ-5D, and visual analogue scale measures. Int J Health Policy Manag. 2015;4:733–40.

42. Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with thalassemia. Indian J Pediatr. 2007;74:727–30.

43. Janssen B, Szende A. Population norms for the EQ-5D [Internet]. In: Szende A, Janssen B, Cabases J, editors. Self-reported population health: An international perspective based on EQ-5D. Dordrecht: Springer Netherlands; 2014 [cited 15 Oct 2019]. p. 19–30. https://doi.org/10.1007/978-94-007-7596-1_3

44. Adib-Hajbaghery M, Poormansouri S, Ahmadi M. Psychometric evaluation of the Persian translation of the thalassemia-specific quality of life questionnaire. J Nurs Meas. 2017;25:202-17.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Shah F, Telfer P, Velangi M, Pancham S, Wynn R, Pollard S, et al. Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational study. eJHaem. 2021;2:738–749. https://doi.org/10.1002/jha2.282